Dr Merchan on Key Data Supporting Pembrolizumab-Based Regime

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

Related Keywords

Jaimer Merch , , Division Of Medical Oncology , Department Of Medicine , Clinical Trials Program , University Of Miami Health System , Sylvester Comprehensive Cancer Center , Clinical Oncology Research Program , Medical Oncology , Trials Program , Miami Health System , Cancers Symposium , Advanced Rcc , Pembrolizumab , Axitinib , Lenvatinib ,